Differential effects of low and high doses of Taxol in anaplastic thyroid cancer cells: Possible implication of the Pin1 prolyl isomerase

Experimental Oncology

Volumn 30, Issue 3, 2008, Pages 190-194

  Pushkarev, V M ^a   Starenki, D V ^b   Saenko, V A ^c   Pushkarev, V V ^a   Kovzun, O I ^a   Tronko, M D ^a   Popadiuk, I D ^a   Yamashita, S ^c  

^a V P Komisarenko Institute of Endocrinology and Metabolism of the Ukraine Academy of Medical Sciences   (Ukraine)

^b HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

^c NAGASAKI UNIVERSITY   (Japan)

Author keywords

Anaplastic thyroid cancer; Apoptosis; Cell cycle; Prolyl isomerase Pin1; Taxol

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MITOGENIC AGENT; PACLITAXEL; PEPTIDYLPROLYL ISOMERASE PIN1; PROTEIN P53; RETINOBLASTOMA PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DEATH; DOSE RESPONSE; DRUG MECHANISM; HUMAN; HUMAN CELL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; THYROID CANCER; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NECROSIS; PACLITAXEL; PEPTIDYLPROLYL ISOMERASE; PHOSPHORYLATION; RETINOBLASTOMA PROTEIN; THYROID NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 53649102984     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Bogdanova TI, Kozyritzky VG, Tronko XD, The Pathology of Thyroid Gland in Children. Atlas. K: Chernobylinterinform, 2000. 280 p.
2. Xix PA, Nicolaides A, Coatesworth AP, Thyroid cancer review 3: management of medullary and undifferentiated thyroid cancer. Int J Clin Pract 2006;60: 80-4.
3. Rowinsky EK, The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Ann Rev Med 1997;48: 353-74.
4. Ain KB, Egorin MJ, DeSimone PA, Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 2000; 10:587-94.
5. Pushkarev VM, Starenki DV, Saenko VA, et al. Molecular mechanisms of the effects of low concentrations of taxol in anaplastic thyroid cancer cells. Endocrinology 2004;145:3143-52.
6. Bergstralh DT, Ti JP-Y. Microtubule stabilizing agents: Their molecular signaling consequences and the potential for enhancement by drug combination. Cancer Treatment Rev 2006;32: 166-79.
7. Takahashi K, Uchida C, Shin RW, et al. Prolyl isomerase, Pinl: new findings of post-translational modifications and physiological substrates in cancer, asthma and Alzheimer's disease. Cell Mol Life Sci 2008;65: 359-75.
8. Bao L, Kimzey A, Sauter G, et al. Prevalent overexpression of prolyl isomerase Pinl in human cancers. Am J Pathol 2004;164: 1727-37.
9. Suizu F, Ryo A, Wulf G, et al. Pinl regulatescentrosome duplication, and its overexpression induces centrosome amplification, chromosome instability, and oncogenesis. Mol Cell Biol 2006;26: 1463-79.
10. Yeh ES, Means AR, PIX1, the cell cycle and cancer. Nat Rev Cancer 2007;7: 381-8.
11. Okamoto K, Sagata N, Mechanism for inactivation of the mitotic inhibitory kinase Wee 1 at M phase. Proc Natl Acad Sci USA 2007;104: 3753-8.
12. Gallo G, Giordano A, Are RB proteins a potential substrate of Pinl in the regulation of the cell cycle? J Cell Physiol 2005;205: 176-81.
13. Basu A, Das M, Qanungo S, et al. Proteasomal degradation of human peptidyl prolyl isomerase Pinl-pointing phosphoBcl2 toward dephosphorylation. Neoplasia 2002;4: 218-27.
14. 1S transition and their response to DNA damage. FEBS Letters 2001;490: 117-22.
15. Scars RC, The life cycle of c-Myc. Cell Cycle 2004;3: 1133-7.
16. Gartel AL, Tyner AL, The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Canc Ther 2002;1: 639-49.
17. Capasso H, Palermo C, Wan S, et al. Phosphorylation activates Chkl and is required for checkpoint-mediated cell cycle arrest. J Cell Sci 2002;115: 4555-64.
18. Henley D, Isbill M, Fernando R, et al. Paclitaxel induced apoptosis in breast cancer cells requires cell cycle transit but not Cdc2 activity. Cancer Chemother Pharmacol 2007;59: 235-49.
19. Lu KP, Zhou XL. The prolyl isomerase PIN 1: a pivotal new twist in phosphorylation signalling and disease. Xat Rev Mol Cell Biol 2007;8: 904-16.
20. Mantovani F, Tocco F, Girardini J, et al. The prolyl isomerase Pinl orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP. Struct Mol Biol 2007;14:912-20.
21. Dourlen P, Ando K, Hamdane M, et al. The peptidyl prolyl cis/trans isomerase Pinl downregulates the Inhibitor of Apoptosis Protein Survivin. Biochim Biophys Acta 2007;1773: 1428-37.
22. Becker EB, Bonni A, Pinl in neuronal apoptosis. Cell Cycle 2007;6: 1332-5.
23. Pang RW, Lee TK, Man K, et al. PIN 1 expression contributes to hepatic carcinogenesis. J Pathol 2006;210: 19-25.
24. Li H, Wang S, Zhu T, Pinl contributes to cervical tumorigenesis by regulating cyclin Dl expression. Oncol Rep 2006;16:491-6.
25. Ryo A, Hirai A, Xishi M, A suppressive role of the prolyl isomerase Pin 1 in cellular apoptosis mediated by the deathassociated protein Daxx. J Biol Chem 2007;282: 36671-81.
26. Ryo A, Liou YC, Wulf G, et al. PIN 1 is an E2F target gene essential for Xeu/Ras-induced transformation of mammary epithelial cells. Mol Cell Biol 2002;22: 5281-95.
27. Wulf GM, Ryo A, Wulf GG, et al. Pin 1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin Dl. EMBO J 2001;20: 3459-72.
28. Xakashlma M, Meirmanov S, Naruke Y, Cyclin Dl overexpression in thyroid tumours from a radio-contaminated area and its correlation with Pinl and aberrant beta-catenin expression. J Pathol 2004;202: 446-55.
29. Oberst A, Rossi M, Salomoni P, et al. Regulation of the p73 protein stability and degradation. Biochem Biophys Res Commun 2005;331: 707-12.
30. Janieke RL\ Sohn D, Essmann F, Schulze-Osthoff K, The multiple battles fought by anti-apoptotic p21. Cell Cycle 2007;6:407-13.
31. Vclla V, Zhu J, Frasca F, et al. Exclusion of c-Abl from the nucleus restrains the p73 tumor suppression function. J Biol Chem 2003: 278: 25151-7.
32. Zhang Y, Daum S, Wildemann D, et al. Structural basis for high-affinity peptide inhibition of human Pin 1. ACS Chem Biol 2007;2: 320-8.